Mark T. Bertolini
Known title: Chief Executive OfficerCIK: 0001352552
Mark T. Bertolini's purchase track record
Mark T. Bertolini has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/6/2026 | OSCR | $11.92M | +146.4% | +154.1% | +17.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OSCR | ▼ Sell | Open Market | 488,654 | $13.9M | 6/30/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 135,590 | $3.9M | 6/30/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 555,826 | $16.2M | 6/29/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 58,926 | $1.8M | 6/29/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 441,373 | $12.8M | 6/26/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 149,795 | $4.5M | 6/26/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 597,942 | $17.1M | 6/25/2026 | View on chart |
| OSCR | ▼ Sell | Open Market | 17,200 | $500K | 6/25/2026 | View on chart |
| OSCR | ▼ Sell | Tax Withholding | 1,000,001 | $11.9M | 4/6/2026 | View on chart |
| OSCR | ▲ Buy | Open Market | 1,000,000 | $11.9M | 4/6/2026 | View on chart |
| OSCR | ▲ Buy | Option Exercise | 5,733,334 | — | 4/3/2026 | View on chart |
| OSCR | ▲ Buy | Grant | 1,596,877 | $0 | 3/2/2026 | View on chart |
| OSCR | ▲ Buy | Option Exercise | 955,556 | $0 | 4/3/2025 | View on chart |
| OSCR | ▲ Buy | Option Exercise | 955,555 | — | 4/3/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Oscar Health Analyst Target Rises to $34.19
Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.
Oscar Health Analyst Target Rises to $34.19. Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.